Values First Advisors Inc. Sells 3,966 Shares of Guardant Health, Inc. (NASDAQ:GH)

Values First Advisors Inc. trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 12.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,059 shares of the company’s stock after selling 3,966 shares during the period. Values First Advisors Inc.’s holdings in Guardant Health were worth $857,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Wellington Management Group LLP increased its position in shares of Guardant Health by 188.6% during the third quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after buying an additional 6,618,785 shares during the period. Eventide Asset Management LLC raised its holdings in shares of Guardant Health by 2.0% in the 3rd quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company’s stock valued at $88,028,000 after acquiring an additional 76,762 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Guardant Health by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after purchasing an additional 29,686 shares in the last quarter. ARK Investment Management LLC increased its position in shares of Guardant Health by 233.5% in the third quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock worth $34,701,000 after purchasing an additional 1,059,104 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in Guardant Health by 19.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock valued at $44,732,000 after purchasing an additional 238,037 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 2,652 shares of company stock worth $93,192 in the last 90 days. Company insiders own 5.50% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $43.60 on Wednesday. The firm has a fifty day simple moving average of $38.45 and a two-hundred day simple moving average of $30.81. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GH. Sanford C. Bernstein dropped their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Guggenheim reaffirmed a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. Leerink Partners cut their price objective on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Barclays started coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price objective on the stock. Finally, The Goldman Sachs Group upped their target price on Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Sixteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $42.63.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.